Ian Bell, President of Global Business and Innovation, Alcon

Articles by Ian Bell, President of Global Business and Innovation, Alcon

Investing in Glaucoma Innovation: Q+A with Alcon’s Ian Bell for World Glaucoma Week

ByIan Bell, President of Global Business and Innovation, Alcon

March 1st 2023

Latest Updated Articles

Trending on PharmExec

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program

FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy